After establishing the binding of martinostat within the HDAC catalytic pocket, we examined whether this translates into effective inhibition of key HDAC substrates in TKI-sensitive and TKI-resistant CML cells. Here, HDAC9 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.